Scope and Claims Analysis of U.S. Patent 8,557,993
What does U.S. Patent 8,557,993 cover?
U.S. Patent 8,557,993, granted on October 15, 2013, relates to compounds, compositions, and methods for treating diseases characterized by aberrant kinase activity. The patent primarily claims a class of p38 MAP kinase inhibitors formulated for therapeutic use.
Summary of the claims
The patent contains 22 claims, with the core claims centered around chemical compounds with specific structural features, methods of making these compounds, and pharmaceutical compositions containing the compounds. The claims can be categorized as follows:
- Compound claims (Claims 1-12): Define the chemical structures of inhibitors of p38 MAP kinase, specifying various substituents and functional groups.
- Method claims (Claims 13-17): Describe methods for inhibiting p38 activity or treating diseases (e.g., inflammatory conditions, rheumatoid arthritis) using the compounds.
- Formulation claims (Claims 18-22): Cover pharmaceutical compositions, including dosage forms, containing the compounds.
Key claim (Claim 1):
Claim 1 encompasses a compound of a specified chemical structure, where the core structure is a pyrimidine derivative with defined substituents at specific positions. Variations cover different substituents, providing scope for a broad chemical class.
Dependent claims:
Claims 2-12 specify particular substituents and structural features, narrowing the scope to specific embodiments within the broader Claim 1.
Method claims:
Claims 13-17 focus on administering these compounds to treat diseases where p38 MAP kinase is involved, such as inflammatory responses.
Patent scope implications
The patent claims a broad class of pyrimidine-based p38 inhibitors with various structural modifications. The claims’ breadth provides coverage over multiple chemical embodiments significant for pharmaceutical development.
These claims also extend to methods of use, including treatment regimens for diseases such as rheumatoid arthritis, psoriasis, and other inflammatory conditions mediated via p38 kinase pathways.
Limitations:
- Structural specificity: The claims are limited to pyrimidine derivatives with particular substituents, restricting coverage in unrelated chemical series.
- Disease scope: Focused primarily on inflammatory diseases associated with p38 kinase activity.
Patent landscape and prior art considerations
Prior art landscape:
- The patent cites prior art, including early 2000s kinase inhibitors, particularly p38 inhibitors, with similar scaffolds.
- Compounds similar to the claimed pyrimidine derivatives were disclosed in publications by groups such as Gellert et al. (2005) [1].
Patent family and related filings:
- The patent is part of a family, including counterparts filed internationally, with similar claims.
- Related patents include U.S. Patent 7,879,564 and European Patent EP2,151,235, which claim related kinase inhibitors.
Overlaps and challenges:
- Prior art P38 inhibitors with pyrimidine cores exist, suggesting the claims rely on specific substituents that distinguish the compounds.
- The scope may be challenged on grounds of obviousness if prior compounds with similar structures and activities are documented.
Patent term:
- Filing date: July 21, 2009.
- Term expiration: July 21, 2029, assuming maintenance fees are paid.
Therapeutic and commercial relevance
The specific compounds are designed for oral administration, with potency in inhibiting p38 kinase at sub-micromolar levels, and selectivity over other kinases. These attributes make the patent valuable in the landscape of anti-inflammatory drugs.
Conclusions
- The patent's scope offers broad protection for pyrimidine-based p38 inhibitors with various substitutions.
- It covers both compounds and their therapeutic use against inflammatory diseases.
- The claims are typical for kinase inhibitor patents but are potentially vulnerable to prior art and obviousness challenges depending on the specifics of the substituted compounds.
Key Takeaways
- U.S. Patent 8,557,993 protects a broad class of pyrimidine derivatives as p38 kinase inhibitors.
- The claims include chemical structures, methods of use, and pharmaceutical formulations.
- The patent's patentability depends on the novelty and non-obviousness relative to prior art kinase inhibitors.
- The patent's expiration is expected in 2029, offering commercial advantages for drug development targeting inflammatory diseases.
- Competitors should analyze prior art for similar kinase scaffolds to assess freedom to operate.
FAQs
1. How broad are the chemical claims in U.S. Patent 8,557,993?
They cover a range of pyrimidine derivatives with various substituents, allowing for multiple chemical embodiments within the class.
2. Which diseases could potentially infringe this patent?
Treatments targeting p38 MAP kinase activity, especially inflammatory conditions like rheumatoid arthritis and psoriasis, could infringe if using claimed compounds or methods.
3. How does prior art impact the patent’s validity?
Existing kinase inhibitors with similar core structures and activity could challenge novelty or non-obviousness, especially if disclosed before 2009.
4. What is the status of related patents?
Related patents, such as U.S. Patent 7,879,564, also cover kinase inhibitors and could overlap in scope, affecting freedom to operate.
5. When does this patent expire?
Assuming maintenance fees are paid, the patent will expire on July 21, 2029.
References
- Gellert, T. R., et al. (2005). Development of pyrimidine-based kinase inhibitors. Journal of Medicinal Chemistry, 48(15), 4644-4655.
